WallStreetZenWallStreetZen

NASDAQ: ROIV
Roivant Sciences Ltd Stock Forecast, Predictions & Price Target

Analyst price target for ROIV

Based on 6 analysts offering 12 month price targets for Roivant Sciences Ltd.
Min Forecast
$15.00+32.16%
Avg Forecast
$18.83+65.93%
Max Forecast
$23.00+102.64%

Should I buy or sell ROIV stock?

Based on 6 analysts offering ratings for Roivant Sciences Ltd.
Strong Buy
Strong Buy
4 analysts 66.67%
Buy
2 analysts 33.33%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their ROIV stock forecasts and price targets.

ROIV stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-07-10Find Out Why
lockedlocked$00.00+00.00%2024-05-31
lockedlocked$00.00+00.00%2024-04-03
lockedlocked$00.00+00.00%2024-04-03Find Out Why
lockedlocked$00.00+00.00%2024-03-25
Wolfe Research
Top 25%
76
BuyInitiates Coverage On$17.00+49.78%2024-02-15

1 of 1

Forecast return on equity

Is ROIV forecast to generate an efficient return?
Company
N/A
Industry
73.55%
Market
80.58%

Forecast return on assets

Is ROIV forecast to generate an efficient return on assets?
Company
N/A
Industry
31.45%

ROIV earnings per share forecast

What is ROIV's earnings per share in the next 2 years based on estimates from 3 analysts?
Avg 1 year Forecast
-$1.12-120.24%
Avg 2 year Forecast
-$1.21-121.8%

ROIV revenue forecast

What is ROIV's revenue in the next 3 years based on estimates from 6 analysts?
Avg 1 year Forecast
$160.4M+28.52%
Avg 2 year Forecast
$241.7M+93.66%
Avg 3 year Forecast
$586.2M+369.76%
ROIV's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

ROIV revenue growth forecast

How is ROIV forecast to perform vs Biotechnology companies and vs the US market?
Company
61.48%
Industry
37.21%
Market
10.62%
ROIV's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
ROIV's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

ROIV vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ROIV$11.35$18.83+65.93%Strong Buy
ASND$138.08$190.88+38.24%Strong Buy
PCVX$82.39$104.00+26.23%Strong Buy
RVMD$45.14$45.75+1.35%Strong Buy
BPMC$117.78$117.69-0.07%Buy

Roivant Sciences Stock Forecast FAQ

Is Roivant Sciences Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 6 Wall Street analysts covering (NASDAQ: ROIV) stock is to Strong Buy ROIV stock.

Out of 6 analysts, 4 (66.67%) are recommending ROIV as a Strong Buy, 2 (33.33%) are recommending ROIV as a Buy, 0 (0%) are recommending ROIV as a Hold, 0 (0%) are recommending ROIV as a Sell, and 0 (0%) are recommending ROIV as a Strong Sell.

If you're new to stock investing, here's how to buy Roivant Sciences stock.

What is ROIV's earnings growth forecast for 2025-2026?

(NASDAQ: ROIV) Roivant Sciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 14.45%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 19.03%.

Roivant Sciences's earnings in 2024 is $4,348,926,000.On average, 3 Wall Street analysts forecast ROIV's earnings for 2025 to be -$829,806,206, with the lowest ROIV earnings forecast at -$1,004,661,658, and the highest ROIV earnings forecast at -$694,398,499.

In 2026, ROIV is forecast to generate -$893,853,386 in earnings, with the lowest earnings forecast at -$1,004,661,658 and the highest earnings forecast at -$701,785,717.

What is ROIV's revenue growth forecast for 2025-2027?

(NASDAQ: ROIV) Roivant Sciences's forecast annual revenue growth rate of 61.48% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.21%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.62%.

Roivant Sciences's revenue in 2024 is $124,795,000.On average, 6 Wall Street analysts forecast ROIV's revenue for 2025 to be $118,480,635,738, with the lowest ROIV revenue forecast at $81,998,120,577, and the highest ROIV revenue forecast at $183,180,846,482. On average, 6 Wall Street analysts forecast ROIV's revenue for 2026 to be $178,531,331,429, with the lowest ROIV revenue forecast at $108,592,105,629, and the highest ROIV revenue forecast at $286,919,549,839.

In 2027, ROIV is forecast to generate $433,066,055,970 in revenue, with the lowest revenue forecast at $158,086,466,698 and the highest revenue forecast at $838,737,352,450.

What is ROIV's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: ROIV) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 31.45%.

What is ROIV's Price Target?

According to 6 Wall Street analysts that have issued a 1 year ROIV price target, the average ROIV price target is $18.83, with the highest ROIV stock price forecast at $23.00 and the lowest ROIV stock price forecast at $15.00.

On average, Wall Street analysts predict that Roivant Sciences's share price could reach $18.83 by Jul 10, 2025. The average Roivant Sciences stock price prediction forecasts a potential upside of 65.93% from the current ROIV share price of $11.35.

What is ROIV's Earnings Per Share (EPS) forecast for 2025-2026?

(NASDAQ: ROIV) Roivant Sciences's current Earnings Per Share (EPS) is $5.55. On average, analysts forecast that ROIV's EPS will be -$1.12 for 2025, with the lowest EPS forecast at -$1.36, and the highest EPS forecast at -$0.94. In 2026, ROIV's EPS is forecast to hit -$1.21 (min: -$1.36, max: -$0.95).

What is ROIV's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: ROIV) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.